Press Release|Articles|May 15, 2025
Camber Pharmaceuticals Announces Addition of Temozolomide Capsules, USP
Listen
0:00 / 0:00
Key Takeaways
- Temozolomide Capsules, USP is an alkylating drug for treating glioblastoma and anaplastic astrocytoma in adults.
- Indications include newly diagnosed glioblastoma with radiotherapy, maintenance treatment, and refractory anaplastic astrocytoma.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Temozolomide Capsules, USP to the portfolio.
Temozolomide Capsules, USP is an alkylating drug indicated for the treatment of adults with:
- Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment
- Anaplastic astrocytoma
- Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma
- Treatment of adults with refractory anaplastic astrocytoma
Temozolomide Capsules, USP are available in the following strengths and sizes:
- 5 mg | 5 and 14 count
- 20 mg | 5 and 14 count
- 100 mg | 5 and 14 count
- 140 mg | 5 and 14 count
- 180 mg | 5 and 14 count
- 250 mg | 5 count
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKD Outcome Set Elevates Patient-Reported Measures
2
FDA Expands Accelerated Approval of Sevabertinib to First-Line HER2-Mutant NSCLC
3
In-Hospital Dapagliflozin Speeds Decongestion in Heart Failure
4
Tozorakimab Reduces COPD Exacerbations Across Eosinophil Levels in Phase 3 Trials
5